Your route to market can change who owns compliance

For a regulated or claim-sensitive product, channel, claims and compliance should be designed together — not handed to separate teams and reconciled at the end.

KosovTeam Consulting · Research Note

Reviewed by Alexey Kosov

Evidence checked: 5 October 2026

Method note: AI-assisted research and drafting were used to expand source coverage and structure the analysis. Source selection, interpretation, claim boundaries and public release remain human-gated.

If you are choosing between direct sales and a distributor, the commercial decision may also change who owns regulatory work. If you change the claim made for the same product, the regulatory pathway or evidence burden may change. And if a market already expects evidence for an attribute such as low volatile organic compound (VOC) content, that attribute may be an entry condition rather than a competitive advantage.

The practical lesson is simple: do not optimise the channel, the claim and the compliance path independently.

A more useful market-entry model is:

claim × intended use × buyer/use case × route to market × compliance owner × evidence.

The point is not to turn a commercial team into lawyers or technical specialists. It is to expose the dependencies early enough to ask the right specialist question before money is committed.

When a distributor can become the compliance owner

Australia gives a clear example.

In the cross-border case described by the Australian Industrial Chemicals Introduction Scheme (AICIS), the party importing the chemical is the “introducer”. When a foreign company uses an Australian agent or distributor to import the chemical, AICIS says that Australian party is the introducer. It must register and is responsible for the relevant compliance and reporting obligations.

If the foreign supplier exports directly to Australian customers, AICIS says the foreign business may itself be the introducer and may need to register before the chemical is exported.

That means the question “direct or distributor?” can change more than sales coverage.

It can change:

– who registers;
– who maintains the regulatory process;
– who holds required records;
– who manages reporting obligations;
– and where regulatory capability must exist operationally.
A distributor may be attractive because of local reach and relationships. But a strong commercial distributor is not automatically a strong compliance operator. The reverse is also true: a route that preserves more direct commercial control may bring more operating obligations back to the supplier.

The decision should compare both layers.

Claims can change the regulatory pathway

A second dependency is easy to miss because teams often treat claims as a marketing decision made after product and compliance work.

The Australian Therapeutic Goods Administration (TGA) explicitly notes that the intended purpose and claims made for a product can determine the type of good and the regulatory requirements that apply. Its guidance on borderline disinfectant and antiviral products shows how different claims can move products into different regulatory treatments.

The transferable lesson is not that every product follows the same Australian rule. It does not.

The useful lesson is that claim language can be a regulatory variable.

A commercially stronger claim may require different evidence, different classification or additional obligations. A weaker claim may be easier to support but less distinctive in the market.

So the right question is not:

“What is the strongest claim we can write?”

It is:

“What is the strongest commercially useful claim that our evidence can support within an acceptable regulatory pathway?”

Evidence can be a threshold rather than a differentiator

The same problem appears on the buyer side.

NABERS Indoor Environment assesses building conditions including indoor air quality. Green Star guidance also sets explicit VOC-related evidence expectations for products such as paints, adhesives and sealants in relevant building-rating contexts.

For a supplier, this changes how an attribute such as “low VOC” should be interpreted.

It may be:

– a genuine differentiator;
– a specification threshold;
– a qualification requirement;
– evidence that reduces buyer risk;
– or simply the baseline needed to enter the conversation.
Those roles are commercially different.

A technically positive attribute is not automatically a positioning advantage. If the target buyer or specification framework already expects the attribute, the value may lie in proving compliance reliably rather than advertising the attribute loudly.

A compact decision map

Before choosing a launch configuration, put the dependencies in one view.

CLAIM

What exactly will we say the product does?

EVIDENCE

What tests, documentation or authoritative material support that claim?

INTENDED USE

Where, how and by whom will the product be used?

BUYER / SPECIFIER

Who can require, reject, recommend or purchase it?

CHANNEL

Direct sale, importer, distributor, contractor, specifier-led route, ecommerce, or another path?

COMPLIANCE OWNER

Which legal or operating entity is responsible for registration, classification, documentation, reporting or specialist sign-off?

UNKNOWN / SPECIALIST GATE

Which question cannot responsibly be answered from commercial research alone?

This map is useful because contradictions become visible before launch.

A distributor can look commercially attractive but be unwilling to own the required compliance process.

A claim can look powerful but lack the evidence needed to support it.

A specification framework can make an environmental attribute necessary without making it differentiating.

A direct-sales route can look simple until the foreign supplier discovers that an obligation it assumed would sit locally now sits with it.

What this changes in a market-entry decision

A market-entry brief should not end with “market attractive” or “distributor identified”.

It should show how the proposed configuration works as a system:

– which buyer and use case are being targeted;
– which claim is commercially useful and supportable;
– which evidence is required;
– which route carries the product;
– who owns the relevant obligations;
– which assumptions remain unresolved;
– and which specialist question must be answered next.

That is the difference between describing a market and preparing a decision.

Limits

This note does not provide Australian legal advice, chemical classification, therapeutic-goods determination, certification, efficacy assessment or compliance sign-off.

The examples show why commercial and regulatory choices can interact. They do not determine the obligations of any specific product or company.

Product category, formulation, intended use, claim language, supply model and jurisdiction-specific facts can change the answer. Where those facts matter, local legal, regulatory, technical or testing specialists should make the relevant specialist determination.